Key points are not available for this paper at this time.
e20665 Background: Inhibitors of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) have therapeutic efficacy in patients with advanced NSCLC. We examined the patterns of response in NSCLC patients treated in a single institution. Methods: We performed a retrospective analysis of patients treated at the Winship Cancer Institute of Emory University with PD-1 and PD-L1 inhibitors on clinical trials or enrolled in an IRB approved biorepository protocol. Clinical and demographic data were collected and response evaluation by RECIST 1.1 was recorded. Results: A total of 31 patients were analyzed. All patients had advanced stage disease with the following characteristics: median age 67.5, 69% male, 69% Caucasian, 91% former and current smokers, 50% adenocarcinoma, and 44% squamous histology. Treatment characteristics (n): nivolumab in 20, pembrolizumab in 9, and atezolizumab in 3 patients. Best treatment response was partial response (PR) in 28%, stable disease (SD) in 31%, and disease progression (PD) in 41%. The median time to progression was 2.3 months. The 9 patients who achieved PR had disease involving the lung only (n = 5), or minimal disease in extrathoracic lymph nodes and bones (n = 3) or brain (n = 1). In six patients with liver metastases, there were no responders and only 2 patients with SD. Conclusions: In our dataset, no objective responses were seen in patients with liver metastases. All clinical responders had primarily intrathoracic disease with limited lymph node, osseous, or CNS involvement. Strategies to improve responsiveness of checkpoint therapy in patients with hepatic involvement should be investigated.
Pillai et al. (Fri,) studied this question.